Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Bone: Giant cell tumour of bone

Written2003-06Ramses G Forsyth, Pancras CW Hogendoorn
N. Goormaghtigh Institute of Pathology, 5 Blok A, University Hospital Ghent, B-9000 Ghent, Belgium
Updated2017-11Arjen Cleven, Judith Bovée
Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands. J.V.M.G.Bovee@lumc.nl

(Note : for Links provided by Atlas : click)

Abstract

Abstract Review on giant cell tumor of bone, with data on clinics, histopathology and genetics

Identity

ICD-Topo C400-C403,C408-C414,C418-C419 BONES & JOINTS
ICD-Morpho 9250/1 Giant cell tumour of bone
Atlas_Id 5150
Phylum Bones::Giant cell tumor
Other namesOsteoclastoma
A characteristic well-defined eccentric, lytic subchondral lesion involving the epiphysis and metaphysis. The borders are well defined and usually not sclerotic. Pathologic fracture is present in 5-10% of giant cell tumours. Dynamic MRI shows a fast uptake and a slow wash out of contrast.

Classification

Note Giant cell tumor of bone is a locally aggressive primary bone neoplasm.

Clinics and Pathology

Disease Locally destructive, mono-ostotic tumoral lesion, typically presenting in the meta-epiphysis of long tubular bones with predilection for the knee region of skeletally mature patients (more than 95% of the patients is older than 25 years). Poly-ostotic lesions are exceptionally rare, counting for less than 1% of all cases. In these cases especially brown tumour of hyperparathyreoidism should be considered, which may look histologically identical. Although defined as a benign lesion, adjacent soft tissue invasion, angiovascular invasion and pulmonary metastases (1%) may occur.
Phenotype / cell stem origin Primitive mesenchymal stromal cell.
Embryonic origin Mesoderm.
Etiology The exact origin is still unknown, but data obtained from ultrastructural analyses and cell cultures, as well as novel molecular data, suggest that the stromal cell, or mononuclear spindle cell, is neoplastic. The mononuclear rounded cells and the osteoclastic giant cells are seen as reactive. Therefore, some suggest that stromal cell tumour is a better name, because this fits more precisely the concept of the mononuclear spindled cell (stromal cell) as neoplastic.
Epidemiology This tumour represents 8% of all primary and approximately 20% of benign primary bone tumours. Mostly affecting adults in the third, fourth and fifth decade of life (72%). It is very rarely seen under the age of 10 years (1,3%). There is a slight female predominance (male/female ratio: 46,6%/53,4%).
Clinics Pain of several weeks to months duration and a constantly expanding mass on X-ray, primary in the epiphysis, leading to cortex destruction, pathological fracture and soft tissue invasion. Finally ulceration of the skin occurs if not threatened. A pathological fracture could occasionally be the first sign of this tumour.
 
Mixture of three cellular components composites the tumour: tumoral spindle shaped mononuclear cells, reactive rounded mononuclear cells and diffusely scattered osteoclast type giant cells. Note that mitoses are strictly limited to the first cell type.
Pathology A mixture of four components can be distinguished:
  • S pindled-shaped and rounded mononuclear cells,
  • Osteoclastic-type giant cells and small blood vessels.
    The spindle-shaped mononuclear cells are regarded as neoplastic. This cell type is thought to arise from the primitive mesenchymal stromal cell. Conventional mitotic figures are restricted to mononuclear cells. If atypical forms or strong nuclear atypia is noted, a secondary sarcomatous malignancy is almost always present. Secondary changes may be present like osteoid deposits, foci of fibrosis, collections of foamy cells or cystic degeneration. Secondary aneurysmal bone cyst formation is present in 6,5% of the cases. Mostly this is restricted to younger patients (median of 14 years).

    In the 2013 WHO classification, grading of histopathological features of GCTB is not considered predictive for clinical behaviour including risk for recurrent or metastatic disease. Originally, giant cell tumors of bone were histological graded into 3 grades according to Jaffe (1940) or into 4 grades (Netherlands Committee on Bone Tumours).

  • Treatment Surgical intervention is the treatment of choice and therapeutic inhibition of osteoclast formation and activity with denosumab (RANK-RANKL inhibitor) provides another modality of treatment. Mostly a curettage followed by local adjuvant cryosurgery or phenol instillation is sufficient to eradicate this lesion and to save the joint. The use of polymethylmetacrylate for filling the cavity after curettage additively decreases the percentage of recurrences. An added advantage of using cement is that recurrences are detected sooner. Sometimes 'en bloc' resection is needed to be curative. Pulmonal metastases are treated by local excision.
    Evolution Non-treatment always leads to destruction of cortical bone, to soft tissue invasion and finally to ulceration of the skin. Local recurrences can occur following proper treatment, mostly indicating less radical initial resection.
    Prognosis Good, despite of recurrences and pulmonary metastases. In general much is depending on the surgical technique and expertise in combination with the histological grade of this tumour. Although pulmonary metastases may occur in rare cases, angiovascular invasion does not have any significant influence on its prognosis. The mortality rate due to giant cell tumour is about 4%.

    Genetics

    Note A specific driver mutation in the histone 3.3 gene H3F3A (p.Gly34) was recently identified in approximately 92% of giant cell tumours of bone. H3F3A mutation detection can be used as a diagnostic tool for the distinction of giant cell tumor of bone from other giant cell-containing tumors. A subset of the mutations can be easily detected using a G34W mutation specific antibody.

    Cytogenetics

    Note No recurrent chromosomal structural or numeric aberrations of importance have been detected yet.
    When confronted with a rearrangement, especially concerning 16q22 or 17p3, an associated aneurysmal bone cyst should be excluded.
    Cytogenetics
    Morphological
    The most frequent chromosomal anomaly is telomeric association. Comparing telomere length of giant cell tumours to this of leukocytes of the same patient, a reduction has been demonstrated. Most commonly affected telomeres are 11p, 13p, 14p, 15p, 19q, 20q and 21p.

    Bibliography

     
    H3F3A (Histone 3
    Amary F, Berisha F, Ye H, Gupta M, Gutteridge A, Baumhoer D, Gibbons R, Tirabosco R, O'Donnell P, Flanagan AM
    3) G34W Immunohistochemistry: A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone Am J Surg Pathol
    PMID 28505000
     
    Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone
    Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gundem G, Davies H, Nik-Zainal S, Martin S, McLaren S, Goodie V, Robinson B, Butler A, Teague JW, Halai D, Khatri B, Myklebost O, Baumhoer D, Jundt G, Hamoudi R, Tirabosco R, Amary MF, Futreal PA, Stratton MR, Campbell PJ, Flanagan AM
    Nat Genet 2013 Dec;45(12):1479-82
    PMID 24162739
     
    Giant cell tumor of bone
    Bridge JA, Neff JR, Mouron BJ
    Chromosomal analysis of 48 specimens and review of the literature Cancer Genet Cytogenet
    PMID 1728946
     
    Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma
    Cleven AH, Höcker S, Briaire-de Bruijn I, Szuhai K, Cleton-Jansen AM, Bovée JV
    Am J Surg Pathol 2015 Nov;39(11):1576-83
    PMID 26457357
     
    Giant cell tumor of bone: a clinicopathologic study of prognostic factors
    Masui F, Ushigome S, Fujii K
    Pathol Int 1998 Sep;48(9):723-9
    PMID 9778111
     
    Chromosomal anomalies exclusive of telomeric associations in giant cell tumor of bone
    McComb EN, Johansson SL, Neff JR, Nelson M, Bridge JA
    Cancer Genet Cytogenet 1996 Jun;88(2):163-6
    PMID 8640728
     
    Cytogenetics of fine needle aspiration biopsies of sarcomas
    Molenaar WM, van den Berg E, Dolfin AC, Zorgdrager H, Hoekstra HJ
    Cancer Genet Cytogenet 1995 Oct 1;84(1):27-31
    PMID 7497439
     
    Radiologic Atlas of Bone Tumors.
    Mulder JD, Kroon HM, Schü HE, Taconis WK
     
    Giant Cell-Containing Tumors of Bone
    Orosz Z, Athanasou NA
    Surg Pathol Clin 2017 Sep;10(3):553-573
    PMID 28797502
     
    Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics
    Presneau N, Baumhoer D, Behjati S, Pillay N, Tarpey P, Campbell PJ, Jundt G, Hamoudi R, Wedge DC, Loo PV, Hassan AB, Khatri B, Ye H, Tirabosco R, Amary MF, Flanagan AM
    J Pathol Clin Res 2015 Mar 16;1(2):113-23
    PMID 27499898
     
    Clonality studies in giant cell tumor of bone
    Schwartz HS, Eskew JD, Butler MG
    J Orthop Res 2002 Mar;20(2):387-90
    PMID 11918322
     
    Cytogenetic-morphologic correlations in aneurysmal bone cyst, giant cell tumor of bone and combined lesions
    Sciot R, Dorfman H, Brys P, Dal Cin P, De Wever I, Fletcher CD, Jonson K, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, Samson I, Tallini G, Van den Berghe H, Vanni R, Willén H
    A report from the CHAMP study group Mod Pathol
    PMID 11106078
     
    Giant-cell tumour of bone metastasising to the lungs
    Siebenrock KA, Unni KK, Rock MG
    A long-term follow-up J Bone Joint Surg Br
    PMID 9460951
     
    Cytogenetic study of 249 consecutive patients examined for a bone tumor
    Tarkkanen M, Kaipainen A, Karaharju E, Böhling T, Szymanska J, Heliö H, Kivioja A, Elomaa I, Knuutila S
    Cancer Genet Cytogenet 1993 Jul 1;68(1):1-21
    PMID 8330278
     
    Telomeric fusion is a major cytogenetic aberration of giant cell tumors of bone
    Zheng MH, Siu P, Papadimitriou JM, Wood DJ, Murch AR
    Pathology 1999 Nov;31(4):373-8
    PMID 10643009
     

    Citation

    This paper should be referenced as such :
    Cleven AH, Bovée JVMG
    Bone: Giant cell tumour of bon
    Atlas Genet Cytogenet Oncol Haematol. in press
    On line version : http://AtlasGeneticsOncology.org/Tumors/BoneGiantCellTumID5150.html
    History of this paper:
    Forsyth, RG ; Hogendoorn, PCW. Bone: Giant cell tumour. Atlas Genet Cytogenet Oncol Haematol. 2003;7(3):193-196.
    http://documents.irevues.inist.fr/bitstream/handle/2042/37996/06-2003-BoneGiantCellTumID5150.pdf


    Other genes implicated (Data extracted from papers in the Atlas) [ 4 ]

    Genes BCL2L1 CPM EWSR1 THBS2

    External links

    arrayMap Topo ( C40,C41) arrayMap ((UZH-SIB Zurich)   [auto + random 100 samples .. if exist ]   [tabulated segments]
     
     
    Disease databaseBone: Giant cell tumour of bone
    REVIEW articlesautomatic search in PubMed
    Last year articlesautomatic search in PubMed


    © Atlas of Genetics and Cytogenetics in Oncology and Haematology
    indexed on : Wed Dec 6 11:01:24 CET 2017


    Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

    For comments and suggestions or contributions, please contact us

    jlhuret@AtlasGeneticsOncology.org.